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1The heart secretes atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) into the circulation in 
response to myocardial stretching. Atrial cardiomyocytes 
mainly secrete ANP, whereas ventricular cardiomyocytes 
predominantly produce BNP. Coded by the adjacent genes 
NPPA and NPPB in humans, the proANP and proBNP pro-
hormones are cleaved to produce an inactive N-terminal 
fragment and the active hormone. ANP and BNP reduce car-
diac load via increased natriuresis, vasorelaxation, and other 
physiological effects mediated by the natriuretic peptide 
receptor A.1 Both the active hormones and the N-terminal 
fragments may be used as biomarkers of cardiac stress. A 
particularly valuable clinical application is the use of low 
measured BNP or NT-proBNP (N-terminal proBNP) con-
centration to rule out suspected heart failure.2 ANP and BNP 
are, thus, regulators of cardiovascular function and useful 
clinical biomarkers.
See Editorial by Armando 
See Clinical Perspective
Natriuretic peptides are attractive therapeutic targets. 
Overexpression of either NPPA or NPPB in mice leads to 
pronounced hypotension.3,4 Deleting NPPA in mice predis-
poses them to hypertension, but knocking out NPPB trig-
gers cardiac fibrosis instead of inducing hypertension.5–7 In 
contrast to mice, the deletion of NPPB in a hypertensive rat 
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2  Salo et al  Natriuretic Peptide GWAS
model has been reported to decrease survival and increase 
both systolic and diastolic blood pressure (BP).8 In humans, 
the effects of ANP or BNP infusions depend on baseline sta-
tus. Infusions of ANP or BNP in patients having heart failure 
trigger various hemodynamic changes, including a decrease 
in arterial pressure, but in healthy males only induce natriure-
sis without affecting arterial pressure.9–12 Both ANP and BNP 
have a BP-lowering effect in those having essential hyperten-
sion, with BNP surprisingly showing a 2- to 3-fold greater 
potency than ANP despite similar receptor affinity.13,14 A lack 
of association or even a paradoxical negative association of 
ANP with BP has been reported in obese men.15 How heart 
failure, hypertension, or obesity may modify ANP and BNP 
function is incompletely understood. Recombinant BNP has 
also failed to show a clear clinical benefit in treating acute 
decompensated heart failure when used in addition to stan-
dard care.9 A more detailed understanding of ANP, BNP, and 
their physiological role may aid in successfully exploiting 
their potential.
Genetic studies of ANP and BNP in humans are of par-
ticular interest as a large part of the literature regard knock-
out animal models and relatively high doses of intravenous 
infusions. Data on variation in their concentration within the 
normal physiological range are more scarce but necessary to 
understand the function of these peptides under nondiseased 
conditions. The association of human genetic variation with 
circulating ANP and BNP has been studied for selected 
single nucleotide polymorphisms (SNPs).16,17 Four genome-
wide association studies (GWAS) have studied circulating 
BNP or NT-proBNP levels.18–21 The prior studies have asso-
ciated variants near NPPA-NPPB with proANP, BNP, and 
NT-proBNP, and the GWAS have associated trans loci near 
LOXL2, SLC39A8, KLKB1, and GALNT4 with NT-proBNP. 
No genome-wide studies have been published on ANP. The 
prior studies, thus, either did not have genome-wide cov-
erage of genetic variation or did not assay ANP, limiting 
the interpretation of their results. We performed genome-
wide association tests of BNP, NT-proBNP, and midregional 
proANP (MR-proANP) and studied the impact of the natri-
uretic peptide–associated genetic variants on BP. Because 
proBNP is processed peripherally into BNP and NT-proBNP 
that have different circulating half-lives, we also studied 
the ratio of BNP to NT-proBNP concentrations (BNP:NT-
proBNP ratio) as a potential proxy for the processing and 
degradation of BNP, proBNP, and NT-proBNP.1,22
Materials and Methods
MR-proANP, NT-proBNP, and BNP were measured in the GWAS 
discovery (n=4932) and replication samples (n=1373), originally re-
cruited for the FINRISK 1997 study. The National FINRISK Study 
cohorts are collected every 5 years as representative age- and sex-
stratified samples of the populations of 5 geographical areas of 
Finland, described in more detail elsewhere.23,24 We tested the asso-
ciation of genetic variants with natriuretic peptide traits in the GWAS 
discovery and replication samples excluding participants who had 
prevalent diabetes mellitus, heart failure, stroke, or coronary heart 
disease. We then studied the BP associations of the genetic variants 
detected in the GWAS in an independent study population, compris-
ing the FINRISK 1992 (n=4920), FINRISK 2002 (n=5,21), FINRISK 
2007 (n=4996), the Northern Finland Birth Cohort 1966 (NFBC66, 
n=5363), the HBCS (Helsinki Birth Cohort Study, n=1619), the YFS 
(Young Finns Study, n=2443), and the Health2000 (n=1997) co-
horts.23–28 All study cohorts were population-based samples of Finns, 
approved by their respective institutional review committees, and par-
ticipants gave their informed consent.
Natriuretic Peptide and BP Measurements
Natriuretic peptide concentrations were measured in the MORGAM 
Biomarker Laboratory, University of Mainz, Germany, using the 
Abbott Architect i2000 BNP (BNP, UniProt acc. P16860, residues 
103–134), Roche Elecsys 2010 proBNP (NT-proBNP, acc. P16860 
residues 27–134), and B.R.A.H.M.S. MR-proANP KRYPTOR (MR-
proANP, acc. P01160) assays, described in more detail previously.29 
The inter/intra-assay coefficients of variation were 2.11%/4.28% 
(BNP), 2.58%/1.38% (NT-proBNP), and 3.65%/2.33% (MR-
proANP). BP was measured from the participants’ right arm, and 
hypertension was defined as diastolic BP >90 mm Hg or systolic BP 
>140 mm Hg or known use of antihypertensive medication.
Genotyping and Imputation
The GWAS discovery sample and replication samples were genotyped 
using the Illumina HumanCoreExome beadchip at the Wellcome 
Trust Sanger Institute (Cambridge, UK) and at the Broad Institute of 
Harvard and MIT (MA, USA), respectively. The data were prephased 
and imputed using the 1000 Genomes project phase 1 and 3 haplo-
types and a custom haplotype set of 2000 Finnish individuals. After 
quality control (Hardy–Weinberg equilibrium P value <0.01, minor 
allele frequency <1%, imputation quality <0.9, genotyping success 
rate <95%) and removal of rare SNPs (minor allele frequency <1%), 
the discovery phase GWAS data set contained a total of 7 358 451 
SNPs and 4932 samples. Cohorts comprising the BP study popula-
tion were genotyped on various genome-wide genotyping arrays and 
imputed using the same methods as used for the GWAS discovery 
sample (Data Supplement). All genomic coordinates are given using 
the GRCh37 human reference genome.
Association Tests
We used multiple imputation to account for any missing values 
for MR-proANP (N
missing
=0), BNP (N
missing
 =131), and NT-proBNP 
(N
missing
=133) and random-effects meta-analysis to combine results 
from the different cohorts.30 We inverse-normal transformed the na-
triuretic peptide measurements and used linear regression with an ad-
ditive genetic model adjusted for geographical sampling region, age2 
sex, body mass index (BMI), current smoking (yes/no), systolic BP, 
glomerular filtration rate estimated using cystatin C and creatinine as 
proxies, and genotyping batch. We used least absolute shrinkage and 
selection operator regression implemented in the LLARMA package 
for fine-mapping the natriuretic peptide–associated loci to identify 
possible secondary independent variants.31 The genetic association 
tests are described in more detail in the Data Supplement.
We used linear regression implemented in the glm function for R 
to study the association of genetic variants with systolic and diastolic 
BP. We log-transformed systolic (but not diastolic) BP and set the first 
2 genomic principal components, age, sex, BMI, current BP medica-
tion use (yes/no, only for systolic and diastolic BP), study year, and 
genotyping batch as covariates (the latter 2 only for the FINRISK 
samples). For hypertension, we used logistic regression and the same 
covariates excluding BP medication.
Phenotypic Variance Explained by SNPs Genome-
Wide
We used autosomal SNPs from the imputed data set to estimate the 
fraction of phenotypic variance explained by the SNPs genome-wide 
in the participants of the GWAS discovery sample using PLINK 
v1.90 and GCTA v1.25.3.32,33 As a quality control measure, we de-
rived 4 genomic scores corresponding to each of the 4 estimates (for 
MR-proANP, BNP, NT-proBNP, and BNP:NT-proBNP ratio) and 
tested the association of the genomic scores with their respective 
phenotypes in the replication sample (Data Supplement).
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Coassociation With Gene Expression
We investigated the coassociation of SNPs with both natriuretic 
peptides and gene expression in data from 190 left ventricular tis-
sue samples and 159 atrial appendage samples from the Genotype-
Tissue Expression (GTEx) consortium (release V6, October 6, 
2016).34 We used 3 metrics to confirm that the same genetic vari-
ants correlated with both gene expression and natriuretic peptide 
concentrations in a consistent way (Data Supplement): we required 
that the most statistically significant natriuretic peptide–associated 
SNPs (lead SNPs) associated with the genes’ expression levels and 
that both the association P values and the effect estimates (β
s
) were 
correlated across the SNPs in the natriuretic peptide–associated re-
gions. Because P values depend on allele frequencies, we used both 
Spearman rank (for P values) and Pearson product moment (for β
s
) 
correlation coefficients as measures of the correlation between the 
natriuretic peptide and gene expression associations and derived the 
P values empirically.
Results
Baseline Characteristics
The baseline characteristics of the GWAS discovery sam-
ple, the replication sample, and the BP study population are 
described in Table I in the Data Supplement. The strata were 
broadly similar, and the main difference was that participants 
with prevalent cardiovascular disease were not excluded from 
the BP study population.
GWAS and Variance Explained by All SNPs
To quantify the total amount of genetic signal present in the 
data, we first estimated the proportion of variance in the natri-
uretic peptide traits jointly explained by all SNPs genome-
wide. The point estimates were 13.9% for MR-proANP, 13.5% 
for BNP, 23.0% for NT-proBNP, and 17.9% for BNP:NT-
proBNP ratio, but the coarse precision of the estimates pre-
vents ranking the 4 phenotypes in any particular order in terms 
of variance explained (Table II in the Data Supplement). The 
magnitude of the 4 estimates nonetheless indicates that the 
SNPs together explained a moderate proportion of the pheno-
typic variance.
Having estimated the proportion of variance explained by 
all SNPs genome-wide, we tested the SNPs individually for 
association with the phenotypes. Variants in 4 loci near NPPA-
NPPB, PPP3CC, GALNT4, and NCOR12 met the prespecified 
threshold for genome-wide significance P<5×10−8 for associa-
tion (Figure 1; Table 1; Figure I in the Data Supplement; Table 
III in the Data Supplement). We selected the SNP with the 
smallest P value (lead SNP) at each locus for replication. Only 
the association of rs701041 with MR-proANP near NCOR12 
did not replicate (P=0.94). Associations near NPPA-NPPB and 
GALNT4 have been reported previously, whereas the associa-
tion of rs7000551 with BNP:NT-proBNP ratio on chromosome 
8 near PPP3CC is a novel finding.16–20 Fine-mapping the loci 
using least absolute shrinkage and selection operator regression 
identified independent secondary signals near NPPA-NPPB 
and GALNT4. Three independent SNPs near NPPA associated 
with MR-proANP levels, whereas 2 independent SNPs near 
GALNT4 associated with BNP:NT-proBNP ratio.
Previously detected associations replicated successfully 
in the present data in terms of the direction of association 
(Table IV in the Data Supplement). Of these, all but 1 of the 
cis associations near NPPA-NPPB also reached statistical 
significance. Two of the 3 previously published trans asso-
ciations, rs13107325 in SLC39A8 and rs3733402 in KLKB1, 
associated with BNP:NT-proBNP ratio in the meta-analy-
sis of the discovery and replication samples (rs13107325 
P=2.19×10−9; rs3733402 P=0.00277) and the meta-analysis 
P value of rs13107325 with NT-proBNP (P=0.00496) was 
also nominally significant. The third, rs6557662 in LOXL2, 
did not reach statistical significance. None of the trans loci 
associated with BNP or MR-proANP.
Most common variants are thought to affect phenotypes 
by altering gene expression.35,36 We, thus, studied data from 
190 left ventricular tissue samples and 159 atrial appendage 
samples from the GTEx consortium to identify coassociation 
of SNPs with both natriuretic peptide traits and gene expres-
sion.34 The results of these tests, together with those of the 
fine-mapping tests with least absolute shrinkage and selection 
operator regression, are presented in detail below for the loci 
meeting genome-wide significance in the present study.
NPPA-NPPB on Chromosome 1
SNPs associating with the natriuretic peptide on chromosome 
1 were located near the NPPA and NPPB genes (Figure 2; 
Figure II in the Data Supplement). Previously, associations 
in this locus have been reported using a GWAS strategy for 
NT-proBNP and a candidate SNP approach for ANP.16–20 To 
extend the previously reported results, we focus here on the 
extensive panel of SNPs and the more detailed phenotyping, 
which were not available in the prior studies.
The NPPA-NPPB locus contained 3 initial association 
signals for BNP, NT-proBNP, and BNP:NT-proBNP ratio, 
depending on which of the phenotypes was tested (Table 1; 
Table III in the Data Supplement). Rs198379, situated 2055 
base pairs downstream from the last exon of NPPB, associ-
ated with BNP (P=4.42×10−52). For NT-proBNP and BNP:NT-
proBNP ratio, rs61761991 was the most statistically significant 
SNP (P=8.76×10−68 and P=4.81×10−103, respectively), and 
least absolute shrinkage and selection operator regression 
detected rs12406089 as a secondary signal for NT-proBNP 
(P=8.31×10−48). However, neither of these 2 SNPs associ-
ated with BNP when rs198379 was included in the model. 
The NPPA-NPPB locus, therefore, harbored only 1 vari-
ant, rs198379, independently associated with both BNP and 
NT-proBNP, with every C allele increasing BNP concentration 
by ≈4.5 pg/mL and NT-proBNP concentration by 9.6 pg/mL.
Three SNPs associated independently with MR-proANP 
at the NPPA-NPPB locus (Table 1). The most statistically 
significant was rs3753584 (P=3.85×10−13), but the effect 
sizes of the 3 SNPs were broadly similar. Each allele of 
the SNPs correlated with a 2.5 to 5.0 pmol/L difference in 
MR-proANP concentration. The SNPs are found ≈40 kb 
downstream from NPPA within an area bound by regulatory 
proteins in human cardiomyocytes (ENCODE: Encyclopedia 
of DNA Elements, https://www.encodeproject.org, experiment 
ENCSR000ENJ).37 Because obesity disturbs the association 
of MR-proANP with BP, we studied the effect of body mass 
on the SNP associations by introducing body mass*SNP inter-
action terms to the regression models.15 The interaction terms 
were statistically nonsignificant (P>0.05) for both BMI as a 
continuous variable and obesity (BMI>30) as a categorical 
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4  Salo et al  Natriuretic Peptide GWAS
variable. Furthermore, because NPPA and NPPB are sepa-
rated by <10 kb, any variant in this region might affect either 
both genes or only 1 of the 2. We explored this by fitting 
models containing all of the previously mentioned SNPs of 
the NPPA-NPPB locus and found that SNPs associated with 
MR-proANP did not associate with BNP or NT-proBNP 
and vice versa (Table V in the Data Supplement), indicat-
ing that their effects were specific to either MR-proANP or 
NT-proBNP (and BNP).
Gene expression profiling in human cardiac tissue sam-
ples confirmed that the associations of SNPs with BNP or 
MR-proANP concentration and with NPPB and NPPA gene 
Figure 1. Genome-wide association study P values. P values of the genome-wide association tests and their genomic locations. Y axis 
cut at Y=18, the peak on chromosome 1 extends to Y=80.
Table 1. Association of Genetic Variants With Natriuretic Peptides in the Genome-Wide Significant Loci
Trait SNP Chromosome Position
Alleles* 
(MAF)
Imputation 
Quality†
Genes (Distance‡, 
Location) Model P
GWAS
P
REPLICATION
β (SE; 95% CI) P
COMBINED
BNP
rs198379 1 11915467 t/C (0.365) 0.989 NPPB (3.5 kb, 3′) GWAS 6.85×10−41 7.99×10−13
0.249 (0.0164; 
0.217 to 0.282)
4.42×10−52
BNP:NT-
proBNP
rs61761991 1 11918444 c/T (0.029) 0.996
NPPB (0.5 kb,  
coding exon)
GWAS 7.17×10−79 5.71×10−26
1.114 (0.0517; 
1.013 to 1.215)
4.81×10−103
 
rs7000551 8 22276251 a/G (0.369) 0.994
SLC39A14 (38.6 kb, 
intronic) PPP3CC  
(22.5 kb, 5′)
GWAS 2.16×10−8 0.0248
0.109 (0.0181; 
0.073 to 0.144)
2.00×10−9
 
rs11105298 12 89876143 t/C (0.211) 0.992
POC1B (59 kb, intronic) 
GALNT4 (43.2 kb, 3′)
GWAS 3.06×10−18 4.11×10−6
0.21 (0.0213; 
0.169 to 0.252)
6.77×10−23
 
rs11105298 12 89876143 t/C (0.211) 0.992
POC1B (59 kb, intronic) 
GALNT4 (43.2 kb, 3′)
Conditional-1 3.67×10−20 2.01×10−6
0.189 (0.02185; 
0.189 to 0.275)
2.96×10−26
 
rs61378614 12 89903654 a/C (0.16) 0.994
POC1B (87 kb, intronic) 
GALNT4 (15.7 kb, 3′)
Conditional-1 1.70×10−10 0.0453
0.101 (0.03242; 
0.101 to 0.228)
4.13×10−7
MR-
proANP
rs3753584 1 11864586 t/C (0.149) 1
MTHFR (3 kb, intronic) 
NPPA (43.5 kb, 3′)
GWAS 4.63×10−38 3.48×10−7
0.275 (0.038; 
0.201 to 0.35)
4.19×10−13
 
rs4845875 1 11824133 A/c (0.355) 0.944
C1orf167 (11 kb, 
intronic) NPPA  
(84 kb, 3′)
Conditional-2 3.53×10−7 0.0031
−0.156 (0.0198; 
−0.156 to −0.079)
3.37×10−9
 
rs6540997 1 11827355 A/g (0.274) 0.995
C1orf167 (8 kb, 
intronic) NPPA  
(80.8 kb, 3′)
Conditional-2 9.03×10−10 0.0326
0.074 (0.0195; 
0.074 to 0.171)
7.13×10−7
 
rs3753584 1 11864586 t/C (0.149) 1
MTHFR (3 kb, intronic) 
NPPA (43.5 kb, 3′)
Conditional-2 1.85×10−20 1.80×10−4
0.162 (0.023; 
0.162 to 0.282)
3.85×10−13
 
rs701041 12 124999344 G/c (0.106) 0.928
NCOR2 (126 kb, 
intronic)
GWAS 1.23×10−8 0.9381
−0.088 (0.0782; 
−0.241 to 0.066)
0.2624
NT-
proBNP
rs61761991 1 11918444 c/T (0.029) 0.996
NPPB (0.5 kb,  
coding exon)
GWAS 1.72×10−51 5.33×10−18
−0.766 (0.044; 
−0.853 to −0.68)
8.76×10−68
 
rs61761991 1 11918444 c/T (0.029) 0.996
NPPB (0.5 kb,  
coding exon)
Conditional-3 3.85×10−43 1.26×10−15
−0.782 (0.0425; 
−0.782 to −0.616)
1.41×10−60
 
rs12406089 1 11921181 c/G (0.291) 0.995 NPPB (2.2 kb, 5′) Conditional-3 2.45×10−33 3.54×10−14
0.201 (0.0172; 
0.201 to 0.264)
8.31×10−48
 
rs10858906 12 89934474 c/T (0.21) 0.996 GALNT4 (15.2 kb, 5′) GWAS 1.08×10−12 0.0388
−0.12 (0.0338; 
−0.186 to −0.054)
3.91×10−4
Association tested with an additive genetic model using single SNP (GWAS) or conditional models which included all SNPs of each model simultaneously. All models adjusted for geographical 
sampling region, age, age2, sex, current smoking status (yes or no), systolic blood pressure, estimated glomerular filtration rate, and genotyping batch. Genomic positions given relative to the 
GRCh37 reference genome build. BNP indicates B-type natriuretic peptide; MAF, minor allele frequency; MR-proANP, midregional proatrial natriuretic peptide; and NT-proBNP, aminoterminal 
pro-B-type natriuretic peptide.
*Alleles given as (reference allele)/(effect allele) with minor alleles in lower case letters.
†IMPUTE info metric. Rs4845875 was directly genotyped with missing genotypes imputed.
‡Median distance to the transcription start sites of the candidate gene(s).
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expression were positively correlated. In left ventricular tis-
sue samples, SNPs associated with circulating MR-proANP 
concentration also associated with NPPA expression level 
(Figure III in the Data Supplement; Spearman rank correlation 
of P values, P=0.014), and SNPs associated with BNP con-
centration also associated with NPPB expression (P=0.004). 
Furthermore, the effect estimates for circulating MR-proANP 
concentration and NPPA expression in the left ventricle cor-
related (Pearson r=0.611; P=0.024) as did those for BNP and 
NPPB (r=0.735; P=0.001). A somewhat attenuated trend was 
also present in the atrial appendage samples, where the corre-
lations between the effect estimates were statistically signifi-
cant (MR-proANP versus NPPA r=0.508; P=0.021 and BNP 
versus NPPB r=0.481; P=0.033), but the correlations between 
association P values were not. In addition to NPPA and 
NPPB, the correlations were also significant for EXOSC10 
and ENSG00000272482 (with MR-proANP) and EXOSC10 
and MTHFR (with BNP). The regulatory effects underlying 
the MR-proANP and BNP associations near NPPA-NPPB 
may, therefore, be stronger in the left ventricle compared with 
the atrium and also selectively affect the expression of other 
nearby genes.
PPP3CC and GALNT4 on Chromosomes 8 and 12
Rs7000551 on chromosome 8 near PPP3CC associated 
with BNP:NT-proBNP ratio (P=2.27×10−9). This correlation 
was driven by an effect on the NT-proBNP concentration as 
rs7000551 associated with NT-proBNP (P=3.72×10−5) but not 
with BNP (P=0.87) in the discovery GWAS sample. However, 
only the association of rs7000551 with BNP:NT-proBNP 
ratio met genome-wide significance and replicated. The gen-
otype-specific mean BNP:NT-proBNP ratios for rs7000551 
(AA=0.386; AG=0.412; GG=0.463) suggest an additive or 
multiplicative genetic effect with each G-allele raising the atio 
by ≈0.04 U or 10%.
The association peak on chromosome 8 extends from 
the 3′ end of SLC39A14 into the promoter region and 5′ end 
of PPP3CC, with rs7000551 itself located in an intron of 
SLC39A14 (Figure 3). When we studied the coassociation 
of SNPs with BNP:NT-proBNP ratio and gene expression, 
PPP3CC and 2 antisense RNA genes ENSG00000245025 
and ENSG00000248738 matched the prespecified criteria. 
SNPs associated with increased BNP:NT-proBNP ratio also 
associated with reduced expression of PPP3CC in both atrial 
and left ventricular tissue samples (atrial appendage, Pearson 
r=−0.70; P=0.006 and left ventricle, r=−0.81; P=0.021; 
Figure III in the Data Supplement). The coassociation with 
the 2 RNA genes was significant only in the left ventricular 
tissue samples. Both the physical location near the promoter 
of PPP3CC and the coassociation with its expression, there-
fore, suggest that the BNP:NT-proBNP ratio–associated SNPs 
tag a regulatory variant that alters the expression of PPP3CC 
in the heart.
SNPs near POC1B and GALNT4 on chromosome 12 
associated with NT-proBNP and BNP:NT-proBNP ratio. 
Rs11105298 and rs61378614, located in different introns of 
the POC1B gene (Figure 3), independently associated with 
the ratio (P=1.52×10−26 and P=3.98×10−9, respectively). The 
genes’ expression on chromosome 12 did not show a clear 
coassociation with BNP:NT-proBNP ratio because none of 
them was significant for all 3 predefined criteria.
Association With BP
Having identified the set of SNPs associated with the natri-
uretic peptide traits in the genome-wide significant loci, we 
next studied their correlation with systolic BP, diastolic BP, 
and hypertension in an independent sample. We fitted all SNPs 
simultaneously in each locus, excluding rs61761991 and 
rs12406089 on chromosome 1, which did not independently 
Figure 2. SNPs associated with natriuretic peptides on chro-
mosome 1 near NPPA and NPPB. Linkage disequilibrium on 
chromosome 1 near NPPA and NPPB. R2 and D′ calculated with 
Haploview v4.2 from 22 374 unrelated Finnish samples. Genes 
are depicted as annotated in GENCODE v19, potential regula-
tory regions identified by digital genomic footprinting in human 
cardiac myocytes (ENCODE: Encyclopedia of DNA Elements, 
experiment number ENCSR000ENJ) indicated by the black 
graph. SNPs independently associated with midregional proatrial 
natriuretic peptide (MR-proANP) colored with blue, SNPs inde-
pendently associated with B-type natriuretic peptide (BNP) or 
NT-proBNP (N-terminal pro-B-type natriuretic peptide) colored in 
pink. SNPs associated with MR-proANP or NT-proBNP in previ-
ous studies colored in black.
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associate with BNP. After genotyping quality control, the 
study sample contained 27 059 participants with both BP mea-
surements and SNP genotypes available.
The 3 SNPs associated with MR-proANP also associated 
weakly with BP (Table 2; Figure IV in the Data Supplement). 
The point estimates of the MR-proANP increasing alleles’ 
effects were ≈0.25 mm Hg (diastolic BP) and 0.50 mm Hg 
(systolic BP). Only 1 of these SNPs was independently asso-
ciated with hypertension as a binary end point (rs3753584; 
P=6.8×10−4). To assess the combined effect of the genetic 
differences in MR-proANP concentration on BP, we formed 
an allele-counting score of the 3 SNPs. The score explained 
2.36% of the variance in MR-proANP concentration and a 
unit increase in the score associated with a 9% decrease in 
the odds ratio for hypertension (odds ratio=0.91; SE=0.0283; 
P=8.2×10−4).
In contrast to MR-proANP, none of the SNPs correlated 
with BNP, NT-proBNP, or BNP:NT-proBNP ratio associ-
ated with BP. Rs198379, associated with NPPB expression 
and circulating BNP levels, did not associate with systolic 
or diastolic BP when adjusted for the nearby MR-proANP–
correlated SNPs. SNPs near PPP3CC and GALNT4, corre-
lated with NT-proBNP and BNP:NT-proBNP ratio, similarly 
did not associate with BP or hypertension.
Discussion
We performed a GWAS of circulating MR-proANP, BNP, 
and NT-proBNP concentration and BNP:NT-proBNP con-
centration ratio in 4932 samples with replication in 1373 
samples. We then studied the effect of the natriuretic peptide–
associated loci on systolic BP, diastolic BP, and hyperten-
sion in 27 059 additional samples. We detected a novel locus 
for BNP:NT-proBNP ratio on chromosome 8 near PPP3CC 
and fine-mapped 2 published loci on chromosomes 1 and 12 
for their association with ANP and BNP and BP. The entire 
genome-wide SNP data explained from 14% to 23% of the 
variation in the natriuretic peptide traits in our population-
based sample. These estimates are similar to those, for exam-
ple, BMI (14%) or systolic BP (24%) published elsewhere, 
showing that the natriuretic peptide traits considered here 
have an additive genetic component comparable to traditional 
cardiovascular risk factors.38
The present study is the first to assess the NPPA-NPPB 
locus with a dense SNP panel simultaneously for MR-proANP, 
BNP, and NT-proBNP, extending the results of previous inves-
tigations.16–21 We identified 3 statistically independent cis vari-
ants associated with MR-proANP, and 1 variant associated with 
BNP and NT-proBNP. Analysis of gene expression data sug-
gests that the protein-level cis associations stem from effects on 
NPPA and NPPB gene expression, affecting both atrial and ven-
tricular tissue. Furthermore, even if the 2 genes are separated 
by <10 000 bp, their transcriptional regulation is decoupled to 
the extent that the ANP-associated SNPs had no observable 
effect on BNP and vice versa. Each of these SNPs, however, 
correlates with both MR-proANP and BNP concentrations, if 
the analysis is not adjusted for the other SNPs. This is crucial 
for the interpretation of results from Mendelian randomization 
studies using SNPs in this locus as instruments, such as those 
performed in relation with type 2 diabetes mellitus.39
SNPs on chromosome 8 near SLC39A14 and PPP3CC 
associate with BNP:NT-proBNP ratio. SLC39A14 belongs to 
the same large family of solute carrier proteins as SLC39A8 
in the previously detected NT-proBNP associated locus 
on chromosome 4, but it is difficult to assess whether this 
is only coincidental.19,40 SNPs associated with increased 
BNP:NT-proBNP ratio correlated with decreased expression 
Figure 3. B-type natriuretic peptide (BNP):NT-proBNP (N-terminal pro-B-type natriuretic peptide) associated SNPs on chromosomes 8 
and 12. Association of SNPs with BNP:NT-proBNP ratio on chromosomes 8 and 12 after meta-analyzing the results from the genome-
wide association study (GWAS) and replication samples with lead SNPs from the GWAS indicated with purple diamonds.
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of PPP3CC in both left ventricular and atrial tissue samples, 
whereas no such correlation was present for SLC39A14. 
PPP3CC codes for 1 of the 3 alternative catalytic subunits 
of calcineurin, a phosphatase with a wide range of functions 
including the regulation of cardiac hypertrophic signaling.41 
Originally characterized as a testis-specific calcineurin sub-
unit, PPP3CC has been later detected in multiple tissues.34 
Because of its central role in spermatogenesis, drugs inhibit-
ing PPP3CC have been suggested as a potential male con-
traceptive.42 Our results indicate that systemic inhibition of 
calcineurin containing the subunit coded by PPP3CC may 
have unintended cardiovascular side effects.
Two independent SNPs near POC1B and GALNT4 asso-
ciated with NT-proBNP levels and BNP:NT-proBNP ratio 
in our study. An association of a SNP with NT-proBNP in 
this locus has been previously reported in whites.19 Analysis 
of gene expression in cardiac tissue failed to highlight any 
of the nearby genes but, as previously noted, GALNT4 is an 
attractive candidate.19 It codes for an aminoacyltranferase that 
initiates O-linked glycosylation, and proBNP is known to 
be O-glycosylated.43,44 According to data presented here, the 
association near GALNT4 is specific to NT-proBNP, support-
ing the hypothesis that proBNP may be a target of GALNT4.
Because BNP and NT-proBNP are produced as a single 
polypeptide, deviations in their circulating concentration ratio 
should reflect their differential secretion or removal, the pro-
cessing of proBNP, or factors disturbing the detection of the 
peptides. The latter is probably the case with rs61761991, 
located within the region of the NT-proBNP prohormone 
(NP_002512.1:p.Arg72His) used as the antigen to prepare the 
assay’s primary antibody.45,46 The variant, which effectively 
blocked the signal of the NT-proBNP assay, is rare or absent 
in other populations but significantly enriched in Finns, where 
the frequency of the T allele is ≈3%.47 One in 20 Finns will, 
therefore, have a measured concentration of NT-proBNP, 
which is ≈50% lower than the corresponding C-terminal BNP 
value, potentially causing false rule-out of suspected heart fail-
ure. The associations of SNPs near GALNT4 with BNP:NT-
proBNP ratio may also relate to the detection of NT-proBNP 
rather than changes in its concentration, if they are indeed 
linked to the possible glycosylation of proBNP by GALNT4. 
How PPP3CC may affect BNP:NT-proBNP ratio is unclear. 
We adjusted the analysis for the estimated glomerular filtration 
rate, but confounding by kidney function cannot be ruled out.
Experimental data has pointed to either similar or differ-
ent cardiovascular effects of ANP and BNP, depending on 
the experimental setting.6–8,48 The results of this study are in 
line with some of the previous studies that identified ANP 
rather than BNP as an important regulator of BP. Genetically 
determined increases in ANP concentration decreased sys-
tolic and diastolic BP, but a smaller genetic decrease in BNP 
did not. Obesity did not modify the associations of SNPs 
with MR-proANP, showing that the transcriptional regula-
tion of NPPA is at least partially unaffected by the reported 
ANP-decreasing effect of high body mass.15,49 According to 
data presented here, earlier genetic associations of the NPPA-
NPPB locus with BP were driven by ANP-associated variants 
and should not be taken as evidence of any BP lowering effect 
of BNP.16 We conclude that there are interesting differences 
between ANP and BNP in humans that are yet to be fully 
elucidated and that genetics provides unique insights into the 
effects of lifelong alterations of these hormones.
Table 2. Independent Effects of Genetic Variants on Natriuretic Peptides and Blood Pressure
SNP Chr Position Alleles*
Candidate 
Genes
GWAS and Replication  
(n=6296)
Blood Pressure Study Population 
(n=27 059)
BNP,  
pg/mL
NT-proBNP, 
pg/mL
BNP:NT-
proBNP Ratio
MR-proANP, 
pmol/L
Diastolic 
BP, mm Hg
Systolic BP, 
mm Hg
Hypertension 
(OR)
rs4845875
1 11824133 A/c NPPA 0.84, ns. 5.00, ns. 0.01, ns.
−2.40, 
P=2.1×10−8
0.40, 
P=0.0033
0.63, ns. 1.00, ns.
rs6540997
1 11827355 A/g NPPA 0.11, ns. −2.20, ns. −0.01, ns.
3.10, 
P=5.8×10−7
−0.25, ns.
−0.47, 
P=0.029
0.93, ns.
rs3753584
1 11864586 t/C NPPA 1.50, ns. 8.70, ns. −0.00, ns.
5.00, 
P=1.2×10−6
−0.38, 
P=0.022
−0.36, ns.
0.88, 
P=6.8×10−4
rs198379
1 11915467 t/C NPPB
4.50, 
P=1.2×10−20
9.60, 
P=7.2×10−19
−0.00, ns. 0.33, ns. −0.02, ns. −0.29, ns. 1.00, ns.
rs7000551
8 22276251 a/G
SLC39A14 
and PPP3CC
−0.34, ns. −3.80, ns.
0.03, 
P=5.4×10−9
−0.11, ns. 0.16, ns. −0.07, ns. 1.00, ns.
rs11105298
12 89876143 t/C GALNT4 0.66, ns.
−7.40, 
P=0.0067
0.06, 
P=3×10−26
1.30, ns. −0.01, ns. −0.04, ns. 1.00, ns.
rs61378614
12 89903654 a/C GALNT4 0.71, ns. −4.40, ns.
0.04, 
P=4.1×10−7
1.00, ns. 0.23, ns. 0.38, ns. 0.99, ns.
Independent effects of SNPs from regression models where, per each locus, all SNPs were simultaneously included. Effects estimated using untransformed trait 
values, P values derived using untransformed (diastolic BP), inverse-normal transformed (natriuretic peptides), or log-transformed (systolic BP) values. For natriuretic 
peptide traits, the models were adjusted for geographical sampling region, age, age2, sex, current smoking status (yes/no), systolic BP, estimated glomerular filtration 
rate, and genotyping batch. For BP traits, the models were adjusted for the first 2 genomic principal components, age, sex, BMI, current BP medication use (yes/no, only 
for systolic and diastolic BP), cohort year, and genotyping batch (the latter 2 only for the FINRISK samples). BP indicates blood pressure; BNP, B-type natriuretic peptide; 
MR-proANP, midregional proatrial natriuretic peptide; NT-proBNP, aminoterminal pro-B-type natriuretic peptide; and SNP, .
*Alleles given as (reference allele)/(effect allele) with minor alleles in lower case letters.
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CLINICAL PERSPECTIVE
Atrial natriuretic peptide and B-type natriuretic peptide are unique hormones secreted by cardiomyocytes, often used in the 
diagnostics of heart failure. They bind to the same receptor, but unexpected differences in their effects have been reported 
in both human and animal models. We used genome-wide association analysis to study genetic variation affecting their 
circulating concentration, identifying 8 variants near the genes NPPA, NPPB, PPP3CC, and GALNT4. Subsequently, we 
investigated the correlation between the natriuretic peptide–associated genetic variants and blood pressure. Genetic variants 
lowering the concentration of midregional proatrial natriuretic peptide associated with higher blood pressure, but we did 
not observe a similar blood pressure correlation with genetic variants affecting B-type natriuretic peptide or NT-proBNP 
(N-terminal pro-B-type natriuretic peptide). The effect sizes of the midregional proatrial natriuretic peptide correlated 
genetic variants on blood pressure were small, from 0.25 to 0.50 mm Hg per allele. Their combined effect, however, associ-
ated with a 9% difference in the odds ratio for hypertension, contributing significantly to the burden of high blood pressure 
in the general population.
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2Supplemental Methods
Genotyping and imputation
The GWAS discovery sample was genotyped using the Illumina HumanCoreExome beadchip at the
Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK. SNPs with clustering probability < 95%,
genotyping success rate < 95%, minor allele frequency (MAF) < 1%, or P < 10-6 for an exact test of Hardy-
Weinberg equilibrium (HWE) were removed. Samples with more than 5% of the genotypes missing or a
mismatch in reported and genotype-determined sex were excluded. The data was then pre-phased with
SHAPEIT v1 and imputed with IMPUTE v2.2.2 using the 1000 Genomes phase 1 (September 2013)
reference haplotypes.[1-3] After imputation, we removed SNPs with more than 5% of genotypes missing,
minor allele frequency (MAF) <1%, imputation quality <0.9 (IMPUTE INFO metric), and SNPs with P<0.01
for a test on HWE.
The GWAS replication sample was genotyped at the Broad Institute of Harvard and MIT,
Cambridge, MA, US, with the Illumina HumanCoreExome beadchip. Before imputation, we removed
samples which were outliers in terms of genomic principal components or heterozygosity, or had a sex
mismatch or more than 2% of the genotypes missing. In order to produce a uniformly imputed dataset,
we pooled the genotypes of the replication sample with all other genotyped FINRISK samples and used
the same exclusion criteria as before with one exception. Because the number of samples was greater,
we included rarer reliably genotyped SNPs (MAF<5% and call rate>99%) with MAF>0  (Illumina
HumanCoreExome Beadchip array) or MAF>(10/number of samples genotyped on the array) (all other
genotyping arrays). We next pre-phased the genotypes with SHAPEIT v2.r727 and imputed the data with
IMPUTE v2.3.2 using the 1000 Genomes Phase 3 haplotypes augmented with a custom haplotype set of
2,000 Finnish individuals. We then used genotypes from this uniformly imputed FINRISK dataset for all
analyses subsequent to the discovery GWAS.
3The additional cohorts in the blood pressure study population were genotyped on various
genotyping arrays: FINRISK 1992, FINRISK 2002, and FINRISK 2007 were genotyped using the Affymetrix
Genome-Wide Human SNP Array, and the Illumina Human610-Quad, HumanCoreExome-24, and
HumanOmniExpress genotyping arrays. NFBC66 was genotyped on the Illumina HumanHap CNV 370k
array, HBCS and Health2000 on the Illumina HumanHap610 quad array, and YFS was genotyped using
the Illumina HumanHap 670k array. The non-FINRISK cohorts were imputed using the same methods as
used for the GWAS discovery sample.
Association tests
We used multiple imputation methods in the "mice" package  of R to account for any missing values for
MR-proANP (N=0), BNP (N=131), and NT-proBNP (N=133).[4] We imputed the rank-normalized data 500
times to be able to ensure convergence and thinned the back-transformed imputations to 10 datasets
for the analyses. We analyzed the 10 resulting datasets separately and pooled the results using base R
implementing the previously described equations (for the GWAS's) or the R package "mice" (all other
tests) in all statistical tests of the natriuretic peptide traits.[4,5]
We tested the association of genetic variants with MR-proANP, BNP, NT-proBNP, and BNP:NT-
proBNP ratio using linear regression. To identify and exclude outliers, we log-transformed the
measurements and excluded values differing more than 4 standard deviation units from the trait mean.
We then inverse-normal transformed the natriuretic peptide measurements and modeled them with a
linear regression model adjusted for geographical sampling region, age, age2, sex, BMI, current smoking
status (yes/no), systolic blood pressure, glomerular filtration rate estimated using cystatin C and
creatinine as proxies (eGFR), and genotyping batch.[6] We extracted the residuals from those linear
regression models and tested the association of the genetic variants with the residuals using SNPTEST.[7]
4To combine the results from the discovery and replication samples, we used random-effects meta-
analysis as implemented in the "rma.uni" function of the "metafor" package for R with the restricted
maximum-likelihood estimator of heterogeneity.[8]
We used ordinary linear regression and LASSO regression to search for multiple independent
association signals at the genome-wide significant loci. Per locus, we first fitted all SNPs simultaneously
in the discovery sample using LASSO regression with fractional model averaging implemented in the
LLARMA package for R, with an additive genetic model and default parameter values.[9] To form a
candidate multi-SNP model for each locus, we selected the top two SNPs in terms of their fractional
resample model inclusion probabilities and all additional SNPs with an inclusion probability of 0.10 or
greater, averaging the inclusion probabilities from the multiply imputed datasets. Next, we tested the
candidate models in the replication sample using ordinary linear regression and declared the SNPs
significant if the point-wise P-values were smaller than 0.05 in both the discovery and replication
samples. Finally, we fitted models with the significant SNPs only and combined the results from the two
samples using the previously described meta-analysis model.
We used linear regression implemented in the "glm" function for R to study the association of
genetic variants with systolic and diastolic blood pressure. We log-transformed systolic (but not
diastolic) blood pressure and set the first two genomic principal components, age, sex, and BMI as
covariates for all tests. For FINRISK samples we additionally included study year and genotyping batch as
covariates. To test the genetic variants for association with hypertension, we used logistic regression
and the same covariates excluding blood pressure medication. We then combined the results from the
different cohorts using the same meta-analysis model as previously.
5Co-association with gene expression
We used the meta-analysis P-values and effect estimates from the present study (for natriuretic peptide
traits) and those from the GTEx eQTL analysis (release V6, Oct 6th 2016; for gene expression) as
measures of association. Because linkage disequilibrium patterns (LD) and allele frequencies are mostly
similar across independent samples, both the association P-values and effect estimates for any two
traits may be expected to correlate even under the null hypothesis of no co-association. We thus
derived the P-values corresponding to the Pearson and Spearman correlation coefficients empirically by
permuting the genotype-phenotype relationship 1,000 times for the natriuretic peptide traits and
analyzing the permuted replicates exactly as done for the GWAS.
To define the regions of association for each genome-wide significant natriuretic peptide-
associated locus, we first located the lead SNP. We then defined the region by sliding a 500 SNP-wide
window away from the lead SNP one variant at a time and stopped extending the region once the
average P-value of association within the window reached 0.5, the expected mean P-value under the
null hypothesis of no association. The regions defined in this way ranged in size from 585,134 to
1,335,097 bp.
Because the GWAS results were exclusively from Finnish samples while the GTEx studied a
cosmopolitan sample of mostly white Caucasians, we excluded variants with the most dissimilar LD
patterns between Finns and other Europeans. For each SNP in a given region, we calculated its
correlation coefficients ri with the i adjacent SNPs at most 100,000 bp away in both Finns and other
Europeans using publicly available 1000 genomes project data.[3] We then derived the root-mean square
deviation (RMSD) in ri between the two populations. Having calculated the RMSD of all SNPs in the
region, we excluded the top 100 SNPs with the greatest RMSD and repeated the procedure until the
average RMSD of the remaining SNPs was smaller than 0.075. This cutoff was selected based on plotting
6the mean RMSD of the retained SNPs against the range of possible cutoff values (from 0 to 2 by
increments of 0.001). For values greater than 0.075, the mean RMSD increased sharply in a non-linear
manner indicating the inclusion of SNPs with particularly high population differences in LD. For values
smaller than 0.075, the relationship was approximately linear.
Phenotypic variance explained genome-wide
We used the uniformly imputed dataset to estimate the fraction of phenotypic variance explained by
the SNPs but modified the imputation quality and HWE test P-value thresholds. Because imputation
quality is  positively correlated with MAF, we included SNPs with IMPUTE INFO metric > 0.3 in order to
avoid unnecessarily penalizing rarer SNPs. Due to the increase in the size of the dataset as compared to
the discovery phase GWAS, we used a numerically smaller HWE P-value limit by excluding SNPs with P <
0.005 for a test on HWE. We estimated the genetic relationship matrix (GRM) of the samples using
PLINK v1.90.[10] Next, we used the GRM to estimate the phenotypic variance explained by the genotypes
with the GCTA v1.25.3 program in the participants of the GWAS discovery sample, setting aside 863
samples for which duplicate genotypes from other genotyping arrays were available to be used in
quality control.[11]
In order to assess the reliability of the estimates of phenotypic variance explained, we derived
four genomic scores corresponding to each of the four estimates and studied the association of the
genomic scores with their respective phenotypes in the replication sample as follows: For each
phenotype, we derived the contribution of the individual SNPs to the total genetic effect using GCTA and
used these as weights to estimate the total genetic effect or genomic score for each of the study
participants for the four traits. The genomic scores were technically robust as the correlation between
the 863 genotyping replicates was high (Pearson's product-moment correlation r > 0.99) for all
7phenotypes. We then tested the association of the genomic scores of MR-proANP, NT-proBNP, BNP, and
BNP:NT-proBNP ratio with said traits in the replication sample using linear regression. We confirmed a
statistically significant association (P < 0.05) with NT-proBNP, BNP, and BNP:NT-proBNP ratio but not
with MR-proANP (Supplemental Table 2).
8Supplemental Tables
Supplemental Table 1. Sample characteristics
GWAS Sample Replication Sample Blood Pressure Study Sample
N 4,932 1,373 27,059
Age (years) 46.18 (21.39) 48.67 (20.5) 42.41 (25.42)
Females (n/%) 2,592 (52.55%) 711 (51.78%) 14,377 (53.13%)
Body Mass Index (kg/m2) 25.73 (5.473) 25.97 (5.116) 25.69 (5.714)
Diastolic Blood Pressure (mm Hg) 82 (15) 82 (14) 80 (16)
Systolic Blood Pressure (mm Hg) 132 (26) 134 (26) 130 (25)
Hypertension (n/%) 2,090 (42.38%) 605 (44.06%) 10,404 (39.3%)
Smoking (n/%) 1,230 (24.94%) 300 (21.85%) 3,893 (24.9%)
Prevalent Heart Failure (n/%) 0 (0%) 0 (0%) na.
Incident Heart Failure (n/%) 289 (5.86%) 84 (6.118%) na.
NT-proBNP (pg/ml) 39.26 (56.49) 46.75 (57.2) na.
MR-proANP (pmol/L) 41.3 (25.2) 43.4 (25.4) na.
BNP (pg/ml) 12.9 (17.6) 14.9 (19.6) na.
Quantitative variables: median (interquartile range)
Qualitative variables: number (proportion)
BNP: B-type natriuretic peptide, MR-proANP: mid-regional proatrial natriuretic peptide, NT-proBNP:
aminoterminal pro-B-type natriuretic peptide
9Supplemental Table 2. Trait variance explained by the genome-wide genotype data
Trait Variance Explained (SE ) Genomic Score Association*
MR-proANP 0.139 (0.071) Beta=1.60, P=0.31
BNP 0.135 (0.070) Beta=2.70, P=0.0049
NT-proBNP 0.230 (0.072) Beta=9.40, P=0.015
BNP:NT-proBNP 0.179 (0.071) Beta=0.03, P=0.0055
Proportion of phenotypic variance explained by autosomal SNPs in the GWAS discovery sample and the
association of the corresponding genomic scores with the traits in the replication sample.
BNP: B-type natriuretic peptide, MR-proANP: mid-regional proatrial natriuretic peptide, NT-proBNP:
aminoterminal pro-B-type natriuretic peptide, SE: standard error
* Beta coefficients given as dimensionless units (BNP:NT-proBNP ratio), pg/ml (BNP and NT-proBNP), or
pmol/L (MR-proANP) per one standard deviation difference in the genomic score
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Supplemental Table 3. Association of genome-wide significant genetic variants with natriuretic peptide traits
Trait SNP* Chr Position Alleles** PGWAS PREPLICATION Beta (95% CI) PCOMBINED
BNP rs3753584 1 11864586 T/C 8.49 × 10-17 1.33 × 10-4 0.2047 (0.1609 to 0.2486) 5.71 × 10-20
rs198379 1 11915467 T/C 6.85 × 10-41 7.99 × 10-13 0.2494 (0.2172 to 0.2816) 4.42 × 10-52
rs61761991 1 11918444 C/T 0.0079 0.0904 -0.1465 (-0.2378 to -0.0552) 0.0017
rs7000551 8 22276251 A/G 0.3909 0.4384 -0.0046 (-0.0414 to 0.0322) 0.8069
rs11105298 12 89876143 T/C 0.3759 0.2768 0.0032 (-0.056 to 0.0623) 0.9168
rs10858906 12 89934474 C/T 0.1767 0.3064 -0.0022 (-0.0699 to 0.0654) 0.9482
rs701041 12 124999344 G/C 0.0047 0.084 -0.0011 (-0.1767 to 0.1745) 0.9905
BNP:NT-proBNP rs3753584 1 11864586 T/C 0.061 0.3392 -0.0523 (-0.1011 to -0.0036) 0.0354
rs198379 1 11915467 T/C 0.0709 0.7244 -0.0321 (-0.0679 to 0.0037) 0.0786
rs61761991 1 11918444 C/T 7.17 × 10-79 5.71 × 10-26 1.1138 (1.0125 to 1.215) 4.81 × 10-103
rs7000551 8 22276251 A/G 2.16 × 10-8 0.0248 0.1085 (0.0731 to 0.144) 2.00 × 10-9
rs11105298 12 89876143 T/C 3.06 × 10-18 4.11 × 10-6 0.2103 (0.1685 to 0.2521) 6.77 × 10-23
rs10858906 12 89934474 C/T 2.06 × 10-17 5.87 × 10-7 0.2105 (0.1686 to 0.2524) 7.27 × 10-23
rs701041 12 124999344 G/C 0.3886 0.5158 -0.0313 (-0.0886 to 0.0261) 0.2858
MR-proANP rs3753584 1 11864586 T/C 4.63 × 10-38 3.48 × 10-7 0.2752 (0.2008 to 0.3495) 4.19 × 10-13
rs198379 1 11915467 T/C 3.97 × 10-7 0.0016 0.0914 (0.0614 to 0.1214) 2.46 × 10-9
rs61761991 1 11918444 C/T 1.97 × 10-4 0.3494 -0.1562 (-0.253 to -0.0595) 0.0016
rs7000551 8 22276251 A/G 0.6066 0.6892 -0.004 (-0.0337 to 0.0258) 0.7944
rs11105298 12 89876143 T/C 0.0369 0.0109 0.0217 (-0.1111 to 0.1545) 0.7489
rs10858906 12 89934474 C/T 0.0457 0.0225 0.0179 (-0.1046 to 0.1404) 0.7746
rs701041 12 124999344 G/C 1.23 × 10-8 0.9381 -0.0876 (-0.2408 to 0.0656) 0.2624
NT-proBNP rs3753584 1 11864586 T/C 1.29 × 10-21 5.65 × 10-6 0.2235 (0.182 to 0.2649) 4.23 × 10-26
rs198379 1 11915467 T/C 4.36 × 10-47 5.76 × 10-16 0.2565 (0.2261 to 0.287) 2.30 × 10-61
rs61761991 1 11918444 C/T 1.72 × 10-51 5.33 × 10-18 -0.7663 (-0.8526 to -0.68) 8.76 × 10-68
rs7000551 8 22276251 A/G 3.72 × 10-5 0.8706 -0.0442 (-0.1086 to 0.0201) 0.1781
rs11105298 12 89876143 T/C 2.54 × 10-11 0.0929 -0.107 (-0.1796 to -0.0344) 0.0039
rs10858906 12 89934474 C/T 1.08 × 10-12 0.0388 -0.1199 (-0.1862 to -0.0536) 3.91 × 10-4
rs701041 12 124999344 G/C 0.0139 0.0366 0.0135 (-0.1602 to 0.1871) 0.8792
Association of SNPs with natriuretic peptides in the GWAS. Association tested with an additive genetic
model adjusted for geographical sampling region, age, age2, sex, current smoking status (yes or no),
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systolic blood pressure, estimated glomerular filtration rate, and genotyping batch. Genomic positions
given relative to the GRCh37 reference genome build.
BNP: B-type natriuretic peptide, MR-proANP: mid-regional proatrial natriuretic peptide, NT-proBNP:
aminoterminal pro-B-type natriuretic peptide
* Genome-wide significant lead SNPs for each trait and locus are marked with bold underlined text
** Alleles given as [reference allele]/[effect allele]
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Supplemental Table 4. Replication of previously published associations.
NT-proBNP MR-proANP BNP BNP:NT-proBNP
Snp Chr Pos Alleles* Beta P AP** Beta P AP** Beta P AP** Beta P AP**
rs1023252 1 11899033 G/T 0.2277 4.71 × 10-43 T[12] 0.0834 3.33 × 10-7 0.1755 1.31 × 10-23 -0.1112 1.13 × 10-8
rs198358 1 11904076 T/C 0.1724 6.71 × 10-20 0.2008 4.60 × 10-27 C[13] 0.1945 1.94 × 10-22 C[13] 0.0156 0.4823
rs5063 1 11907648 C/T 0.2532 1.30 × 10-9 -0.055 0.1813 C[14] 0.1904 0.0041 -0.1637 0.1528
rs198389 1 11919271 A/G 0.2535 1.03 × 10-60 G[15] 0.0905 2.79 × 10-9 0.2462 2.48 × 10-51 -0.0328 0.0705
rs35207557 1 11917620 T/TA 0.2502 2.98 × 10-58 0.0919 2.20 × 10-9 0.2448 5.32 × 10-50 TA[16] -0.0284 0.1585
rs5068 1 11905974 A/G 0.2213 4.26 × 10-6 0.3298 7.68 × 10-30 G[13] 0.1782 4.27 × 10-11 G[13] -0.1265 0.0097
rs549596 1 11916095 T/C 0.2474 4.69 × 10-58 0.0932 8.76 × 10-10 0.2417 8.42 × 10-50 C[16] -0.027 0.1366
rs632793 1 11910677 A/G 0.254 3.80 × 10-59 0.0938 1.30 × 10-9 G[13] 0.2448 1.81 × 10-49 G[13] -0.034 0.0647
rs13107325 4 103188709 C/T 0.1824 0.005 T[17] -0.0498 0.4356 -0.0658 0.3373 -0.4549 2.19 × 10-9
rs3733402 4 187158034 G/A 0.0053 0.9054 0.0136 0.7592 -0.033 0.3429 G[18] -0.0529 0.0028
rs6557662 8 23230898 A/G -0.0061 0.7792 A[16] -0.0189 0.6837 -0.0251 0.3838 -0.0217 0.4283
rs11105306 12 89897388 C/T -0.1159 2.77 × 10-5 C[17] 0.0213 0.7416 -0.0002 0.9935 0.2084 9.55 × 10-22
Association of previously published SNPs with natriuretic peptide traits in the meta-analysis of the GWAS and replication samples. All models
adjusted for geographical sampling region, age, age2, sex, current smoking status (yes or no), systolic blood pressure, estimated glomerular
filtration rate, and genotyping batch.
BNP: B-type natriuretic peptide, MAF: minor allele frequency, MR-proANP: mid-regional proatrial natriuretic peptide, NT-proBNP: aminoterminal
pro-B-type natriuretic peptide
* Alleles given as [reference allele]/[effect allele]
** AP: Previously published trait increasing-allele
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Supplemental Table 5. Multi-SNP models on chromosome 1
Trait SNP Beta SE P
BNP rs198379_C 0.2385 0.03445 4.42 × 10-12
BNP rs3753584_C 0.03386 0.02994 0.2581
BNP rs6540997_G 0.01056 0.02655 0.6909
BNP rs4845875_C 0.01701 0.02356 0.4703
BNP rs61761991_T -0.03811 0.0527 0.4696
BNP rs12406089_G 0.03313 0.05278 0.5302
MR-proANP rs198379_C -0.03905 0.03207 0.2234
MR-proANP rs3753584_C 0.1937 0.05636 5.88 × 10-4
MR-proANP rs6540997_G 0.1249 0.02474 4.47 × 10-7
MR-proANP rs4845875_C -0.1264 0.02197 8.60 × 10-9
MR-proANP rs61761991_T 0.01139 0.04926 0.8171
MR-proANP rs12406089_G 0.06408 0.05276 0.2246
NT-proBNP rs198379_C 0.1347 0.05406 0.0127
NT-proBNP rs3753584_C 0.00616 0.02794 0.8255
NT-proBNP rs6540997_G 0.01158 0.04709 0.8057
NT-proBNP rs4845875_C -0.01402 0.02191 0.5223
NT-proBNP rs61761991_T -0.6503 0.04891 2.42 × 10-40
NT-proBNP rs12406089_G 0.1222 0.05417 0.0241
BNP:NT-proBNP rs198379_C 0.1083 0.04947 0.0286
BNP:NT-proBNP rs3753584_C 0.02899 0.04006 0.4694
BNP:NT-proBNP rs6540997_G -0.02637 0.0508 0.6037
BNP:NT-proBNP rs4845875_C 0.04523 0.02601 0.0821
BNP:NT-proBNP rs61761991_T 1.085 0.05833 3.33 × 10-77
BNP:NT-proBNP rs12406089_G -0.1126 0.03479 0.0012
Multivariate models of SNP-natriuretic peptide association with all identified SNPs on chromosome
included simultaneously. Trait association tested using geographical sampling region, age, age2, sex,
current smoking status (yes or no), systolic blood pressure, estimated glomerural filtration rate, and
15
genotyping batch, and the SNPs (rs198379, rs3753584, rs6540997, rs4845875, rs61761991 and
rs12406089) as the independent variables.
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Supplemental Figures
Supplemental Figure 1. Expected and observed -log10(P-value) distributions of the GWAS.
17
Supplemental Figure 2. Linkage disequilibrium on chromosome 1 near NPPA and NPPB
18
Linkage disequilibrium between SNPs on chromosome 1 near NPPA and NPPB. Genes are depicted as
annotated in GENCODE v19 in Ensembl. R-squared and D' calculated with Haploview v4.2 from 22,374
unrelated Finnish samples for Finns and from genotype data published by the 1000 Genomes Project for
people of African (AFR), American (AMR), Asian (ASN), and European (EUR) ancestry. SNPs
independently associated with MR-proANP colored with blue, SNPs independently associated with BNP
or NT-proBNP colored in pink. SNPs associated with MR-proANP or NT-proBNP in previous studies
colored in black.
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Supplemental Figure 3. Correlation of SNP effects on natriuretic peptides and gene expression
The effect estimates or betas of SNPs on natriuretic peptides (X-axis) and gene expression (Y-axis). Data
is shown for samples from atrial appendages (AA) and left ventricles (LV). SNPs excluded from the
analysis due to population differences in linkage disequilibrium patterns are shown in light red, SNPs
included in the analysis are shown in black.
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Supplemental Figure 4. Independent relative effects of cis SNPs on natriuretic peptides and blood pressure
The effects of cis genetic variants near NPPA and NPPB on natriuretic peptides and blood pressure (BP)
in regression models including all four SNPs simultaneously. The point estimates of the effects,
represented by the markers, were estimated using untransformed trait values and the 95% confidence
intervals, depicted by the vertical lines, were derived assuming normal distribution of the estimates. NT-
proBNP values were scaled from pg/ml to pmol/L using 0.118 as the scaling factor. For the figures on the
bottom row, the estimates were divided by the standard deviations of each trait. For MR-proANP and
NT-proBNP, the models were adjusted for geographical sampling region, age, age2, sex, current smoking
status (yes/no), estimated glomerural filtration rate, and genotyping batch. For systolic and diastolic BP,
the models were adjusted for the first two genomic principal components, age, sex, BMI, current BP
medication use (yes/no), cohort year and genotyping batch (the latter two only for the FINRISK
samples).
21
SD: standard deviation, BP: blood pressure, MR-proANP: mid-regional proatrial natriuretic peptide, NT-
proBNP: aminoterminal pro-B-type natriuretic
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